BIO - Bio-Rad Laboratories, Inc.

NYSE - NYSE Delayed price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
2,802,249
2,802,249
2,922,545
2,545,626
2,311,659
Cost of revenue
1,234,919
1,234,919
1,281,884
1,107,804
1,054,663
Gross profit
1,567,330
1,567,330
1,640,661
1,437,822
1,256,996
Operating expenses
Research development
256,889
256,889
271,657
226,598
202,710
Selling general and administrative
827,825
827,825
879,574
800,267
824,625
Total operating expenses
1,092,214
1,084,714
1,151,231
1,026,865
1,027,335
Operating income or loss
475,116
482,616
489,430
410,957
229,661
Interest expense
38,114
38,114
1,551
21,861
23,416
Total other income/expenses net
-5,199,249
-5,148,775
4,950,270
4,518,542
2,054,836
Income before tax
-4,704,273
-4,704,273
5,438,149
4,907,638
2,261,081
Income tax expense
-1,076,738
-1,076,738
1,192,247
1,101,371
502,406
Income from continuing operations
-3,627,535
-3,627,535
4,245,902
3,806,267
1,758,675
Net income
-3,627,535
-3,627,535
4,245,902
3,806,267
1,758,675
Net income available to common shareholders
-3,627,535
-3,627,535
4,245,902
3,806,267
1,758,675
Basic EPS
-
-121.79
142.61
128.13
58.93
Diluted EPS
-
-121.79
140.83
126.47
58.27
Basic average shares
-
29,785
29,831
29,768
29,843
Diluted average shares
-
29,785
30,208
30,160
30,184
EBITDA
-
-4,528,863
5,573,501
5,067,626
2,418,735